Home » Eurofins Genomics to construct new facility in Louisville

Eurofins Genomics to construct new facility in Louisville

LOUISVILLE, Ky. — Eurofins Genomics LLC, an international provider of DNA sequencing services plans to expand its presence in Louisville with a new manufacturing facility to supply reagents used for virus detection. The company will invest over $35.7 million for the new operation.

Eurofins will construct a 65,000-square-foot facility in Blankenbaker Station Business Park across from its existing location. The new facility will house the company’s manufacturing, research and administrative operations. The facility will produce oligonucleotides – or oligos – which are synthetic DNA used in molecular diagnostic applications.

Oligos are critical for the detection of viruses and are used in PCR-based COVID-19 tests and a variety of other diagnostic applications. The new facility will increase domestic production of oligo and reduce lead times to help support a market vulnerable to supply shortages. Production will support the company’s current partnerships with the U.S. Air Force and the U.S. Department of Health and Human Services. Construction is expected to begin in April and be completed by Q2 2023.

Kentucky’s ideal geographic location and expansive distribution and logistics presence will enable Eurofins to enact fast and reliable distribution of these key reagents throughout the country to help mitigate supply chain issues and support domestic COVID-19 testing.

“The new facility will increase domestic production of oligos to combat current and future pandemics and empower a broader range of research in the molecular diagnostic field,” said Sumit Gupta, president of Eurofins Genomics.

Louisville-based Eurofins Genomics is a life science company that provides genomic products and services to medical, environmental and agricultural partners with locations in the U.S., Europe and Asia. The company is a subsidiary of Luxembourg-based Eurofins Scientific, which was founded in 1981 and employs 55,000 people in over 900 laboratories across 50 countries.

To encourage investment and job growth in the community, the Kentucky Economic Development Finance Authority (KEDFA) today approved Eurofins for up to $300,000 in tax incentives through the Kentucky Enterprise Initiative Act (KEIA). KEIA allows approved companies to recoup Kentucky sales and use tax on construction costs, building fixtures, equipment used in research and development and electronic processing.

By meeting its annual targets over the agreement term, the company can be eligible to keep a portion of the new tax revenue it generates. The company may claim eligible incentives against its income tax liability and/or wage assessments.

In addition, Eurofins can receive resources from Kentucky’s workforce service providers. These include no-cost recruitment and job placement services, reduced-cost customized training and job training incentives.

For more information on Eurofins Genomics, visit EurofinsGenomics.com.

Click here for more Kentucky business news.